Table 1 Demographics of the study population.
From: Quantitative MRI phenotypes capture biological heterogeneity in multiple sclerosis patients
Demographical/clinical characteristics | Cross-sectional | Longitudinal |
|---|---|---|
Number of patients included | 213 | 33 |
Gender: N female/male (% female) | 151/62 (70.9%) | 24/9 (72.7%) |
Age at onset (years): median (range) | 29 (4–68) | 27 (4–68) |
Disease course: Bout onset/primary progressive/unknown (% bout onset) | 208/2/3 (97.6%) | 33/0/0 (100.0%) |
Disease duration (years): median (range) | 8 (0–43) | 6 (1–20) |
Age at imaging (years): median (range) | 39 (19 -71) | 36 (19–69) |
Interval between first and second scan (months): mean (standard deviation) | – | 13.2 (7.9) |
MSSS at imaging: median (range) | 1.61 (0.11–9.45) | 1.21 (0.19–8.50) |
Oligoclonal bands: positive/negative/unknown (% positive) | 175/18/20 (90.6%) | 26/4/3 (86.7%) |
IgG index: median (range) | 0.90 (0.44–4.2) | 0.94 (0.5–4.2) |
Therapy at imaging: N (%) | 133 (62.5%) | 21 (63.6%) |
None | 80 (37.5%) | 12 (36.4%) |
Interferon-beta | 62 (29.1%) | 6 (18.1%) |
Glatiramer acetate | 21 (9.9%) | 2 (6.1%) |
Teriflunomide | 15 (7.0%) | 4 (12.1%) |
Fingolimod | 13 (6.1%) | 3 (9.1%) |
Natalizumab | 14 (6.6%) | 5 (15.2%) |
Other (dimethyl fumarate and alemtuzumab) | 8 (3.8%) | 1 (3.0%) |
